

Oregon Prescription Drug Monitoring Program Advisory Commission

January 17th, 2014 Meeting Minutes

1:00 PM to 4:00 PM

Portland State Office Building

800 NE Oregon Street, Room 918

Portland, OR 97232

ATTENDEES:

Advisory Commission Present: Mike Millard, Chris Apgar, Tara Gregory (for Larisa Jeffries), Lindsay Jenkins, Teresa Keane, Sara Love, John Mcilveen (for Karen Wheeler), Al Turner, Mark Williams

Advisory Commission Absent: Bill Jordan, Tracy Muday

OHA Staff: Lisa Millet, Todd Beran

Decisions
1. The meeting minutes from October 2013 were approved as written.
2. Millard will represent the Advisory Commission as a member of the Oregon Statewide Coalition against Prescription Drug Abuse.

Action Items	Assigned	Status
1. Adjust the number of licensed pharmacists in the to-date report to 3,300 to reflect the number who actually dispense controlled substances.	Murphy	Completed
2. Contact the PDMP vendor to determine if an automated reminder can be sent to master account holders to review system access by delegates.	Beran	Completed
3. Determine if prescriber DEA searches can be audited to evaluate use of this function.	Beran	Completed
4. Check with DOJ to ascertain if PDMP reports can be scanned into patient health records.	Beran	Completed

INTRODUCTIONS

Millard called the meeting to order at 1:10 p.m. Attendees introduced themselves.

OLD BUSINESS

The meeting minutes were reviewed and approved as written – see Decision 1.

NEW BUSINESS

a. Review to-date metrics

Beran reviewed the monthly, year-to-date, and to-date reports. He highlighted that approximately 41 percent of Oregon-licensed prescribers who prescribed at least one prescription listed in the database are authenticated system users.

b. Review PDMP Annual Report

Beran reviewed the 2013 Annual Report located at <http://www.orpdmp.com/reports/>. Members discussed the significant increase in pharmacists' use of the system. Keane asked what pharmacists do when they find unexpected results in a patient report. Beran noted that based on responses from the 2012 survey of pharmacists, they contact providers to verify the prescription. Love noted some pharmacists report information to the appropriate regulatory boards when they find there may be a prescribing issue. Millard confirmed these are common pharmacist practices whether or not a PDMP report is accessed.

While reviewing program objectives, Millet stated that the objectives listed are a starting point for 2014 and are yet to be fully determined. Available resources will be a deciding factor. The focus of the program will continue to be how people use the system and what effect use of the system is having on patient outcomes. Millard stated that a note should be added to PDMP data analysis objective to compare 2012 and 2013 data.

Members discussed use of the system by discipline. Keane stated it would be useful to look at specialty and high-dosage prescribers to help focus outreach efforts further. Turner noted that the top cohort of prescribers should be clarified as the "most frequent prescribers."

c. Preview system changes

Beran presented a demo of the new system changes related to legislative amendments using the PDMP test site. New system functions include delegate account access, master account holder audits of delegate use of the system, and prescriber DEA searches.

OPEN ISSUES

Millard informed the Advisory Commission that he has accepted a position on the Oregon Statewide Coalition against Prescription Drug Abuse. He stated that this group supports legislatively mandating PDMP signup. The members agreed that mandated

PDMP signup was not in the best interest of the program. Members decided that Millard should represent the Advisory Commission on the coalition – see Decision 2.

PUBLIC COMMENT

No public comments were made.

NEXT MEETING DATE

The next PDMP Advisory Commission meeting will be on Friday, April 18th, 2014 in room 918 at the Portland State Office Building.

ADJOURNMENT

The meeting was adjourned at 3:20 PM.